NCT05505994View on ClinicalTrials.gov

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

February 26, 2024

Study Completion Date

September 30, 2024

Conditions
Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism DisordersMetabolic DiseaseEndocrine System Diseases
Interventions
DRUG

DWP16001

DWP16001 A mg tablet

DRUG

Dapagliflozin

Dapagliflozin tablet

DRUG

DWP16001 Placebo

DWP16001 Placebo tablet

DRUG

Dapagliflozin Placebo

Dapagliflozin Placebo tablet

Trial Locations (1)

+86

Peking University People's Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05505994 - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin | Biotech Hunter | Biotech Hunter